CD28
生物
T细胞
抗原
免疫疗法
共刺激
抗体
重组DNA
肿瘤抗原
CD3型
外周血单个核细胞
癌症研究
分子生物学
细胞生物学
免疫学
CD8型
免疫系统
体外
生物化学
基因
作者
Ludger Große‐Hovest,Ingo Hartlapp,Wolfgang Marwan,Gottfried Brem,Hans‐Georg Rammensee,Gundram Jung
标识
DOI:10.1002/eji.200323322
摘要
Endowing tumor cells with costimulatory signals for T cell activation has emerged as a promising strategy for tumor immunotherapy. Costimulatory molecules were either transfected into tumor cells to generate vaccines or were fused, e.g. to antibodies against tumor-associated antigens, to achieve targeted T cell costimulation in vivo. Here we report the production and purification of rM28, a recombinant bispecific single-chain antibody directed to a melanoma-associated proteoglycan and to the costimulatory CD28 molecule on human T cells. We found that a dimer of the recombinant molecule, bound to tumor target cells, induced pronounced T cell activation in peripheral blood mononuclear cell preparations without additional TCR/CD3 stimulation being required. The lytic activity generated after 3 days of stimulation effectively prevented tumor cell growth. However, it was unspecific and predominantly mediated by non T cells. Our findings demonstrate that presentation of a CD28 antibody within a suitable recombinant, bispecific format may result in a "targeted supra-agonistic stimulation" of the CD28 molecule, which leads to effective tumor cell killing after induction of unspecifically lytic cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI